Clinical relevance of BKM120 was further confirmed on primary AML samples obtained from de novo and chemo-resistant patients with different PI3K/Akt/mTOR pathway activation and on MNCs obtained from healthy volunteers. The gene discussed is AKT1; the disease is acute myeloid leukemia.